American Lung Association in California Offers Lung Cancer Patients “Support From Day One”

Lung Association launches new online resource in time for National Lung Cancer Awareness Month

Los Angeles, CA (November 8, 2012)

To support the kickoff of National Lung Cancer Awareness Month, the American Lung Association has launched Facing Lung Cancer: Support from Day One, a new patient and caregiver-focused online lung cancer information resource. This web-based tool offers interactive features that address specific topics of interest for people living with lung cancer and their loved ones.

Facing Lung Cancer: Support from Day One, made possible with financial support from Lilly Oncology, concentrates on the most important information patients need to know from day one of their diagnosis. In addition to providing general lung cancer education, the site allows users to design a customized guide to use during conversation with their lung cancer care team.

“Lung cancer is the most deadly of all cancers here in America, and one in fourteen Americans is affected by this killer,” said Jane Warner, President and CEO, American Lung Association in California. “It is the single most fatal cancer in both men and women, yet it remains largely overlooked. People living with lung cancer need to know that they are not alone.

Facing Lung Cancer  is one more step the Lung Association is taking to help people living with lung cancer. The Lung Association also invests in high quality research to prevent lung cancer, increase the survival rate, and improve lung cancer patients’ quality of life.

Lung Association funded research is being conducted right here in California:  Trever Bivona, MD, PhD of the University of California, San Francisco is focused on lung cancers that are associated with a particular mutation in a gene called EGFR. Patients with this type of lung cancer are treated with a drug called erlotinib (Tarceva), which blocks the mutant form of EGFR. While the treatment induces tumor regression, the cancers develop resistance to the drug. Dr. Bivona hopes to understand how lung cancer becomes resistant to erlotinib.

In addition, Sergei Grando, MD, PhD, DSCI of the University of California, Irvine, is identifying the mechanisms by which tobacco leads to the cancerous transformation of lung cells in the hopes that it will prove useful in preventing lung cancer. The results of this research will contribute to a better understanding of the way in which tobacco leads to cancer, and open the door for new approaches to treatments that will interfere in this process.

“We believe that investing in research and providing helpful resources will transform the way lung cancer is viewed and discussed,” said Warner. “Everyone needs to understand the severity of lung cancer and support the fight for a cure.”